Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03222531 · ClinicalTrials.gov registry record · Phase 2

Expanding the Pool in Orthotopic Heart Transplantation

A Phase 2 study of Hepatitis C and Heart Transplant, sponsored by Mary E. Keebler, MD.

Active
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT03222531: Active Phase 2 study of Hepatitis C and Heart Transplant, sponsored by Mary E. Keebler, MD.

NCT03222531 is a Phase 2 study of Hepatitis C and Heart Transplant that is active but no longer recruiting, run by Mary E. Keebler, MD. The registered enrollment target is 20 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03222531, a Phase 2 study of Hepatitis C and Heart Transplant, is active but no longer recruiting, sponsored by Mary E. Keebler, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment and prophylaxis will be administered, using a transmission-triggered approach for the first scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV Ab+/NAT+ donors, arm 2).

Primary Outcome

Rate of adverse events due to sofosbuvir/velpatasvir (Epclusa) in patients in each experimental group

Interventions

  • DRUG sofosbuvir/velpatasvir

Study Locations (1)

Pennsylvania

  • UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-08-01
Est. Completion 2026-05-31
Phase Phase 2
Mary E. Keebler, MD

1 total trials

What the registry record for NCT03222531 still lists

NCT03222531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which sofosbuvir/velpatasvir is the first listed.

NCT03222531 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03222531 about?

NCT03222531 is a clinical study titled "Expanding the Pool in Orthotopic Heart Transplantation". This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment and prophylaxis will be admin...

What is the current status of trial NCT03222531?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-08-01. Estimated completion is 2026-05-31.

What conditions does trial NCT03222531 study?

This clinical trial studies the following conditions: Hepatitis C, Heart Transplant, Cardiac Transplant.

What interventions are being tested in trial NCT03222531?

The interventions under investigation include: sofosbuvir/velpatasvir (DRUG).

Who is sponsoring clinical trial NCT03222531?

This trial is sponsored by Mary E. Keebler, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03222531 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03222531's enrollment target sits among peer trials

20 94th of 106 higher than 9 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03222531, the US trial registry maintained by the National Library of Medicine. NCT03222531 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.